(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) jumped by a staggering 30.8% in 21 sessions from $8.85 at 2023-02-01, to $11.57 at 11:00 EST on Thursday, after four successive sessions in a row of gains. NASDAQ is dropping 1.08% to $11,940.08, after three sequential sessions in a row of gains.
Viking Therapeutics’s last close was $11.14, 15.8% above its 52-week high of $9.62.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.84%.
More news about Viking Therapeutics (VKTX).
